Cell cycle progression: new therapeutic target for vascular proliferative disease
- PMID: 9665064
- DOI: 10.1161/01.cir.98.1.82
Cell cycle progression: new therapeutic target for vascular proliferative disease
Abstract
Entry into and progression of vascular cells through the cell cycle is considered a key event in vascular proliferative diseases. Multiple growth factors and cytokines have been found to regulate vascular cell proliferation. However, the machinery regulating cell cycle represents the "final common pathway" of these signaling cascades and thus provides an attractive therapeutic target for the prevention of vascular proliferative diseases. This review focuses on the current understanding of the regulation of the cell cycle machinery especially as it relates to vascular cell biology and the feasibility of targeting cell cycle for the prevention of restenosis after balloon angioplasty and bypass vein graft disease.
Similar articles
-
The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):41B-55B. doi: 10.1016/s0828-282x(06)70986-2. Can J Cardiol. 2006. PMID: 16498512 Free PMC article. Review.
-
Vascular smooth muscle cell proliferation as a therapeutic target. Part 1: molecular targets and pathways.Biotechnol Adv. 2018 Nov 1;36(6):1586-1607. doi: 10.1016/j.biotechadv.2018.04.006. Epub 2018 Apr 21. Biotechnol Adv. 2018. PMID: 29684502 Review.
-
Esculetin inhibits Ras-mediated cell proliferation and attenuates vascular restenosis following angioplasty in rats.Biochem Pharmacol. 2003 Jun 1;65(11):1897-905. doi: 10.1016/s0006-2952(03)00161-8. Biochem Pharmacol. 2003. PMID: 12781342
-
B cell translocation gene, a direct target of miR-142-5p, inhibits vascular smooth muscle cell proliferation by down-regulating cell cycle progression.FEBS Lett. 2013 Aug 2;587(15):2385-92. doi: 10.1016/j.febslet.2013.06.005. Epub 2013 Jun 13. FEBS Lett. 2013. PMID: 23770100
-
G beta gamma-mediated signaling: new therapeutic target for proliferative vascular disease.IUBMB Life. 1999 Sep;48(3):257-61. doi: 10.1080/713803509. IUBMB Life. 1999. PMID: 10690635 Review.
Cited by
-
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results.Am Heart J. 2012 Sep;164(3):379-386.e1. doi: 10.1016/j.ahj.2012.05.019. Am Heart J. 2012. PMID: 22980305 Free PMC article. Clinical Trial.
-
Role of Cyclins and Cytoskeletal Proteins in Endometriosis: Insights into Pathophysiology.Cancers (Basel). 2024 Feb 19;16(4):836. doi: 10.3390/cancers16040836. Cancers (Basel). 2024. PMID: 38398227 Free PMC article. Review.
-
The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.Can J Cardiol. 2006 Feb;22 Suppl B(Suppl B):41B-55B. doi: 10.1016/s0828-282x(06)70986-2. Can J Cardiol. 2006. PMID: 16498512 Free PMC article. Review.
-
Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation.Br J Pharmacol. 2001 Apr;132(7):1597-605. doi: 10.1038/sj.bjp.0703945. Br J Pharmacol. 2001. PMID: 11264255 Free PMC article.
-
The GTPase ARF6 Controls ROS Production to Mediate Angiotensin II-Induced Vascular Smooth Muscle Cell Proliferation.PLoS One. 2016 Jan 29;11(1):e0148097. doi: 10.1371/journal.pone.0148097. eCollection 2016. PLoS One. 2016. PMID: 26824355 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical